How are AI caution and 340B payment cuts reshaping biotech this week?

Anthropic CEO Dario Amodei’s tempered outlook on AI drug discovery and Medicare’s proposed 340B payment cuts both signal a cooling in biotech momentum. The week’s roundup highlights that optimism for rapid AI breakthroughs is fading while reimbursement pressures rise, pushing the sector toward operational discipline over expansion.